Skip to main content
Institutional profile

Personalis

Personalis is a precision oncology diagnostics provider focused on advanced cancer genomics, immuno-oncology, and personalized molecular residual disease testing. Its platform is designed to support therapy selection, recurrence monitoring, and clinical development.

  • Highest 2026 tier: Tier II
  • Precision Medicine Diagnostics Providers
  • 1 ranking category

Overview

Personalis is a precision oncology diagnostics provider focused on advanced cancer genomics, immuno-oncology, and personalized molecular residual disease testing. Its platform is designed to support therapy selection, recurrence monitoring, and clinical development.

The company’s relevance lies in its focus on deep molecular profiling and personalized cancer monitoring. As oncology increasingly requires understanding tumor evolution, immune context, and treatment resistance, diagnostics providers with advanced profiling capability are likely to remain important.

Personalis is included in 1 2026 ranking category. Its highest classification is Tier II. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.

Firm facts

Public identityPersonalis
Founded2011
Institution typePrecision Medicine Diagnostics Providers institution
HeadquartersFremont, United States
Primary focusPrecision Medicine Diagnostics Providers
Highest 2026 ranking tierTier II

Principal activities

The company’s relevance lies in its focus on deep molecular profiling and personalized cancer monitoring. As oncology increasingly requires understanding tumor evolution, immune context, and treatment resistance, diagnostics providers with advanced profiling capability are likely to remain important.

Core capability

Precision Medicine Diagnostics Providers

Client relevance

Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.

Execution and verification

Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.

Sector and mandate coverage

Primary category

Precision Medicine Diagnostics Providers

Institutional context

Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.

Market position

Personalis is especially relevant for biopharmaceutical collaborations and clinical trial support, where detailed molecular analysis can help identify patient subgroups and monitor treatment response.

Personalis is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier II.

Competitive context

The relevant peer set varies by category, geography, client segment and mandate. Personalis should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.

Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.

Leadership and governance

Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.

Corporate and public information

The public-facing organization is identified here as Personalis. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.

Corporate and disclosure information
OrganizationPersonalis
HeadquartersFremont, United States
Verification noteConfirm legal entity, licenses, offices and engagement terms directly before appointment or use.

Rankings and recognition

Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.

Related Economy analysis

Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:

Sources and data transparency

Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.

  1. Healthcare Ranking — Top 30 Precision Medicine Diagnostics Providers 2026 — 2026 inclusion and tier classification.
  2. The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
  3. The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
  4. The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.

First published: 29 August 2026

Last substantively reviewed: 29 August 2026

Profile scope: Precision Medicine Diagnostics Providers

This profile has been compiled from publicly available institutional and editorial sources. The profiled organization does not determine its inclusion, editorial characterization or ranking status. Corrections supported by authoritative documentation may be submitted to The Economy Wiki.